LONDON -Activist investor Elliott said GlaxoSmithKline should review its leadership and consider a sale of its consumer ...

GSK has agreed to acquire Rapt Therapeutics, a US-based biotech whose leading drug combats food allergies, in a deal that ...

GlaxoSmithKline will purchase Novartis’ 36.5 percent stake in their consumer healthcare joint venture for $13 billion, according to Reuters. Here are four things to know. 1. The $13 billion ...

Emma Walmsley, the CEO who led the U.K. drugmaker GSK through the Covid-19 pandemic and the transformative spinoff of its consumer-health brands, will step down at the end of the year, the company ...

GSK plc (NYSE:GSK) is one of the best performing pharma stocks in 2025. Jefferies reaffirmed a Buy rating on GSK plc (NYSE:GSK) on January 7 and set a price target of $55.60. The same day, GSK plc ...

In today’s Pharmaceutical Executive Daily, GSK moves to strengthen its immunology pipeline with a $2 billion acquisition of ...

Anyone expecting a new chief executive of GlaxoSmithKline (NYSE:GSK) to take a fresh look at spinning off its consumer health arm should think again. The often-discussed move was always firmly ...

GlaxoSmithKline appointed Brian McNamara CEO of the Consumer Healthcare division. 1. Mr. McNamara most recently served as head of Europe and the Americas at GSK Consumer Healthcare. 2. Prior to ...

GSK said Emma Walmsley would step down after more than eight years as chief executive and named its commercial chief, Luke Miels, to succeed her in the top job. Walmsley, who became CEO of the U.K.